The Illumina & GRAIL deal: Lessons for the Indian Competition Regime
[By Sunidhi Kashyap] The author is a student of Rajiv Gandhi National University of Law, Punjab. Introduction A failed attempt at acquiring a healthcare company involved in developing early cancer detection tests, led to an interesting take on the European Union Merger Regulation (“EUMR”). Illumina, an American biotechnology company manufacturing and selling next generation sequencing (“NGS”) systems, used in developing blood-based tests to detect cancer, wanted to acquire GRAIL, an American healthcare company engaged in developing an early multi-cancer detection test in asymptomatic patients. Illumina had publicly announced its intention to acquire GRAIL for $8 billion in 2020. However, this acquisition embroiled Illumina in a legal battle with both, the EU and the US regulators on account of the anti-competitive nature of this deal. While the unsuccessful deal of Illumina and GRAIL is known for the unique interpretation of Article 22 of EUMR given by the General Court (“GC”), it has also paved a path for regulating combinations. The interpretation given by the GC shows that though the deal was within the threshold limit of notifying the relevant authorities, it still had the potential of stifling innovation in a constantly evolving and emerging market like healthcare. In this context, this post will firstly shed light on the role of Article 22 of EUMR in this deal; secondly, it will discuss the importance of regulating combinations in markets of innovation and lastly, it will identify the lacunae in the Indian competition regime and would suggest a way forward. Article 22 of EUMR and the Illumina-GRAIL deal Illumina is the top supplier of NGS systems and GRAIL was a customer of Illumina, using its NGS systems to develop cancer detection tests. According to the investigation of the European Commission (“EC”), a vertical merger between the two could destroy competition in the market of early cancer detection tests as Illumina would be incentivized to not share its technology with GRAIL’s rivals and consequently, without the essential input from Illumina, GRAIL’s competitors would be put in a disadvantaged place. The market players were apprehensive that post the acquisition, Illumina would monopolize the emerging market of early cancer detection tests by limiting access to its NGS systems. While both the American healthcare companies did not exceed the relevant thresholds and did not have any European dimension it was still subject to scrutiny by the EC. This was possible only because Article 22 of EUMR permits Member States to request the EC to investigate the concentration if it affects competition within the territory of the Member State. When looked closely, Article 22 plays a crucial role by regulating those combinations which fall within the turnover threshold but still carry an adverse effect on competition in a market. Especially, in cases of killer acquisitions, where the nascent firms are bought by the incumbents to prevent any future competition, provisions like Article 22 are important to maintain healthy competition in the market. In India, however, combinations under the Competition Act, 2002 (“The Act”), are looked from an antitrust lens only when it exceeds the turnover or asset thresholds. This “safety net” or the de minimis exemption excludes many combination deals in emerging markets, especially where a tangible product may not be developed yet but its merger with an incumbent firm still poses antitrust concerns. In this context, this article will argue for treating combinations in emerging markets or markets of innovation differently, by accounting for their peculiarities. Markets of Innovation and Antitrust Concerns Emerging or markets of innovation refer to those markets where there is constant scientific development, inventions, technological advancements, improvements or modifications. They largely refer to the research and development (“R&D”) intensive sectors. A unique characteristic of such markets is that it may not necessarily possess a tangible good which is ready to be sold. For instance, in the case of the Illumina and GRAIL deal, the early cancer detection test being developed by GRAIL was not a ready product yet. Despite that, the merger would have stifled innovation and competition in an emerging market which could potentially lead to a reduced consumer choice. In innovation markets, the R&D development is much more fast-paced, making it more volatile than a traditional market. For instance, the infamous IBM “debacle” presents the perfect example of how innovation markets are difficult to predict. In 1969, IBM was a major player with the highest market share in the computer manufacturer sector and was being sued under Section 1 of the Sherman Act for restraint of trade. The case went on till 10 years and towards the end, it was simply dismissed in 1982 because IBM was no longer a monopolist and had lost its dominance in the market. This case shows that R&D firms are always vulnerable to radical changes and their dominance is only temporary. However, this does not mean that antitrust analysis would be completely absent in these ever-evolving markets. Being dominant in such markets for 10-20 years takes substantial resources from the economy and stifles innovation and competition both. Lacunae in the Indian Competition Regime While dealing with combinations in innovation markets, the biggest roadblock is posed by the “safety net” or the thresholds specified under the Act. The thresholds prescribed under the Act are of two types- turnover and asset. Only if a combination surpasses these thresholds would the Competition Commission of India (“CCI”) undertake an investigation for ruling out any appreciable adverse effect on competition in the market. Moreover, given the recent enhancements of these limits and the de minimis exemption, a lot of combination deals fall outside the scope of the Act. Additionally, it seems that the Act has a brick-and-mortar enterprise centric approach which assumes that a firm would traditionally make large investments in assets and aim to obtain a higher turnover. However, in the current technologically advanced times where the internet is progressively reducing the requirement to acquire assets, and firms are becoming dominant without heavy investments, such an approach seems outmoded. Another hindrance with respect to innovation markets is
The Illumina & GRAIL deal: Lessons for the Indian Competition Regime Read More »